Methylated circulating tumor DNA in blood: Power in cancer prognosis and response

Endocrine-Related Cancer

Volumn 23, Issue 3, 2016, Pages R157-R171

  Warton, Kristina ^a   Mahon, Kate L ^a,b   Samimi, Goli ^a  

^a ST VINCENT'S CLINIC   (Australia)

^b Chris O'Brien Lifehouse   (Australia)

Author keywords

Cancer; Circulating DNA; Methylation; Plasma DNA; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; CA 125 ANTIGEN; CAPECITABINE; CIRCULATING TUMOR DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; DOCETAXEL; GLUTATHIONE TRANSFERASE P1; IMATINIB; MITOXANTRONE; PROTEIN MSH2; RETINOIC ACID RECEPTOR BETA; STRATIFIN; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; DNA METHYLATION; DNA SEQUENCE; ESOPHAGUS CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; NEUROBLASTOMA; PATIENT MONITORING; PROMOTER REGION; PROSTATE CANCER; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; GENETICS; NEOPLASMS; PROGNOSIS;

BIOMARKERS, TUMOR; DNA METHYLATION; DNA, NEOPLASM; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84963971785     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0369     Document Type: Review

References (102)

1. Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M et al. 2013 Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clinical Chemistry and Laboratory Medicine 51 1505-1510. (doi:10.1515/cclm-2012-0320)
2. Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, Georgoulias V & Lianidou ES 2014 Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. British Journal of Cancer 110 2054-2062.
3. Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E et al. 2015 Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutation Research 778 46-51.
4. Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomata C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P et al. 2015 Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology 26 1994-1999. (doi:10.1093/annonc/mdv272)
5. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW & Nelson WG 2005 Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clinical Cancer Research 11 4037-4043.
6. Baylin SB & Jones PA 2011 A decade of exploring the cancer epigenome - biological and translational implications. Nature Review Cancer 11 726-734. (doi:10.1038/nrc3130)
7. Bishop HM, Blamey RW, Elston CW, Haybittle JL, Nicholson RI & Griffiths K 1979 Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 2 283-284. (doi:10.1016/S0140-6736 (79) 90295-2)
8. Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D, Byun HM, Jiang J, Marinelli B, Pesatori AC et al. 2007 Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Research 67 876-880. (doi:10.1158/0008-5472. CAN-06-2995)
9. Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P & Buckingham L 2012 CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagnostic Molecular Pathology 21 207-213. (doi:10.1097/PDM.0b013e31825554b2)
10. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF et al. 2003 Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clinical Cancer Research 9 2912-2919.
11. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S & Sanchez-Carbayo M 2010 Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. Journal of Translational Medicine 8 86. (doi:10.1186/1479-5876-8-86)
12. Chen YB, Shu J, Yang WT, Shi L, Guo XF, Wang FG & Qian YY 2011 XAF1 as a prognostic biomarker and therapeutic target in squamous cell lung cancer. Chinese Medical Journal 124 3238-3243.
13. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH, European Organisation for Research and Treatment of Cancer, Limburgs Universitair Centrum & AstraZeneca Pharmaceuticals 2005 Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals Journal of Clinical Oncology 23 6139-6148. (doi:10.1200/JCO.2005.08.156)
14. Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA et al. 2014 DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Research 16 450. (doi:10.1186/s13058-014-0450-6)
15. Das AM, Seynhaeve AL, Rens JA, Vermeulen CE, Koning GA, Eggermont AM & Ten Hagen TL 2014 Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration. Angiogenesis 17 163-177. (doi:10.1007/s10456-013-9385-2)
16. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B et al. 2013 Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine 368 1199-1209. (doi:10.1056/NEJMoa1213261)
17. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H et al. 2005 Detection and quantification of mutations in the plasma of patients with colorectal tumors. PNAS 102 16368-16373. (doi:10.1073/pnas.0507904102)
18. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al. 2008 Circulating mutant DNA to assess tumor dynamics. Nature Medicine 14 985-990. (doi:10.1038/nm.1789)
19. El Messaoudi S, Rolet F, Mouliere F & Thierry AR 2013 Circulating cell free DNA: preanalytical considerations. Clinica Chimica Acta 424 222-230. (doi:10.1016/j.cca.2013.05.022)
20. Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, Perabo FG, Muller SC, von Ruecker A & Bastian PJ 2008 Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. Journal of Urology 179 346-352.
21. Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C et al. 2014 Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Research 74 2160-2170. (doi:10.1158/0008-5472. CAN-13-3392)
22. Feil R & Fraga MF 2012 Epigenetics and the environment: emerging patterns and implications. Nature Review Genetics 13 97-109. (doi:10.1038/nrg3142)
23. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G & Widschwendter M 2005 Circulating tumorspecific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Research 65 1141-1145. (doi:10.1158/0008-5472. CAN-04-2438)
24. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C & Lahm H 2006 Promoter methylation of RASSF1A, RARb and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54 109-116. (doi:10.1016/j. lungcan. 2006.06.017)
25. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D et al. 2012 Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Science Translational Medicine 4 136ra168. (doi:10.1126/scitranslmed.3003726)
26. Fu D, Ren C, Tan H, Wei J, Zhu Y, He C, Shao W & Zhang J 2015 Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine 94 e637. (doi:10.1097/MD.0000000000000637)
27. Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Morimoto K, Tamaki Y & Noguchi S 2012 Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology 83 273-282. (doi:10.1159/000342083)
28. Garcia-Baquero R, Puerta P, Beltran M, Alvarez-Mujica M, Alvarez-Ossorio JL & Sanchez-Carbayo M 2014 Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors. Tumour Biology 35 5777-5786. (doi:10.1007/s13277-014-1767-6)
29. Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, Muller-Holzner E, Marth C & Daxenbichler G 2011 Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Research and Treatment 130 109-117.
30. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Hoyer S et al. 2013 DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. Journal of Clinical Oncology 31 3250-3258. (doi:10.1200/JCO.2012.47.1847)
31. Han J, Lv P, Yu JL, Wu YC, Zhu X, Hong LL, Zhu WY, Yu QM, Wang XB, Li P et al. 2014 Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer. Digestive Diseases and Sciences 59 1160-1168. (doi:10.1007/s10620-013-3007-0)
32. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE & Lumey LH 2008 Persistent epigenetic differences associated with prenatal exposure to famine in humans. PNAS 105 17046-17049. (doi:10.1073/pnas.0806560105)
33. Heyn H & Esteller M 2012 DNA methylation profiling in the clinic: applications and challenges. Nature Review Genetics 13 679-692. (doi:10.1038/nrg3270)
34. Hoffmann AC, Vallbohmer D, Prenzel K, Metzger R, Heitmann M, Neiss S, Ling F, Holscher AH, Schneider PM & Brabender J 2009 Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. Journal of Cancer Research and Clinical Oncology 135 1231-1237. (doi:10.1007/s00432-009-0564-x)
35. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J et al. 2006 Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. Journal of Clinical Oncology 24 4262-4269. (doi:10.1200/JCO. 2005.01.3516)
36. Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VJ, Jadhav RR, Louie AD, Lin CL, Kroczak T et al. 2015 DNA methylation screening of primary prostate tumorsidentifies SRD5A2 and CYP11A1 as candidate markersfor assessing risk of biochemical recurrence. Prostate 75 1790-1801. (doi:1710.1002/pros.23052)
37. Hoshimoto S, Kuo CT, Chong KK, Takeshima TL, Takei Y, Li MW, Huang SK, Sim MS, Morton DL & Hoon DS 2012 AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. Journal of Investigatory Dermatology 132 1689-1697.
38. Ignatiadis M & Dawson SJ 2014 Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Annals of Oncology 25 2304-2313. (doi:10.1093/annonc/mdu480)
39. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD & Knippers R 2001 DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Research 61 1659-1665.
40. Jia Y, Yang Y, Zhan Q, Brock MV, Zheng X, Yu Y, Herman JG & Guo M 2012 Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. Journal of Molecular Diagnostics 14 577-585. (doi:10.1016/j.jmoldx.2012.06.004)
41. Kim Y, Jin D, Lee BB, Cho EY, Han J, Shim YM & Kim DH 2015 RARb2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. Clinical Epigenetics 7 32. (doi:10.1186/s13148-015-0066-4)
42. Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, Liebenberg V, Field JK & Dietrich D 2011 SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. Journal of Thoracic Oncology 6 1632-1638. (doi:10.1097/JTO.0b013e318220ef9a)
43. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ & Hoon DS 2006 Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Research 66 6111-6117.
44. Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, Lu PJ, Chang WL, Lai WW & Wang YC 2014 Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. International Journal of Medical Sciences 11 779-787. (doi:10.7150/ijms.7405)
45. Laird PW 2003 The power and the promise of DNA methylation markers. Nature Review Cancer 3 253-266. (doi:10.1038/nrc1045)
46. Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH & Laurent-Puig P 2002 Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. International Journal of Cancer 100 542-548.
47. Lee MG, Han J, Jeong SI, Her NG, Lee JH, Ha TK, Kang MJ, Ryu BK & Chi SG 2014 XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313. PNAS 111 15532-15537. (doi:10.1073/pnas. 1411746111)
48. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB et al. 2002 Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109 113-124. (doi:10.1016/S0092-8674 (02) 00690-6)
49. Li FF, Yang Y, Wang XL, Hong YY, Wang NF & Chen ZD 2014 Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis. Tumour Biology 35 6011-6020. (doi:10.1007/s13277-014-1796-1)
50. Liggett TE, Melnikov AA, Marks JR & Levenson VV 2011 Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. International Journal of Cancer 128 492-499. (doi:10.1002/ijc.25363)
51. Ling ZQ, Zhao Q, Zhou SL & Mao WM 2012 MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. European Journal of Surgical Oncology 38 326-332.
52. Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S et al. 2013 Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. PLoS ONE 8 e67195. (doi:10.1371/journal. pone.0067195)
53. Liu WB, Cui ZH, Ao L, Zhou ZY, Zhou YH, Yuan XY, Xiang YL, Liu JY & Cao J 2011 Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a. Toxicology and Applied Pharmacology 251 70-78. (doi:10.1016/j.taap. 2010.12.002)
54. Ludwig JA & Weinstein JN 2005 Biomarkers in cancer staging, prognosis and treatment selection. Nature Review Cancer 5 845-856. (doi:10.1038/nrc1739)
55. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW & Lo YM 2002 Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clinical Chemistry 48 421-427.
56. Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G et al. 2014 Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer 111 1802-1809. (doi:10.1038/bjc.2014.463)
57. Martinez-Galan J, Torres-Torres B, Nunez MI, Lopez-PenalverJ, Del Moral R, Ruiz De Almodovar JM, Menjon S, Concha A, Chamorro C, Rios S et al. 2014 ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer 14 59. (doi:10.1186/1471-2407-14-59)
58. Meiers I, Shanks JH & Bostwick DG 2007 Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology 39 299-304. (doi:10.1080/00313020701329906)
59. Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, Khabir A, Frikha F, Kallel L, Amouri A, Frikha M, Sellami-Boudawara T, Gargouri A et al. 2010 Hypermethylation of RARb2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma. Tumour Biology 31 503-511. (doi:10.1007/s13277-010-0063-3)
60. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD & Ralhan R 2010 Clinical significance of Stratifin, ERa and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clinical Biochemistry 43 380-386. (doi:10.1016/j.clinbiochem.2009.11.016)
61. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD & Ralhan R 2012 Clinical significance of promoter hypermethylation of ERb and RARb2 in tumor and serum DNA in Indian breast cancer patients. Annals of Surgical Oncology 19 3107-3115. (doi:10.1245/s10434-012-2323-5)
62. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T & Hosoi H 2009 RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. British Journal of Cancer 100 399-404.
63. Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G et al. 2012 Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecologic Oncology 124 582-588. (doi:10.1016/j.ygyno. 2011.11.026)
64. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ et al. 2005 Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. Journal of Clinical Oncology 23 9351-9358. (doi:10.1200/JCO.2005.02.9876)
65. Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ et al. 2006 Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Research 66 6692-6698.
66. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al. 2013 Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 108-112. (doi:10.1038/nature12065)
67. Nishio M, Sakakura C, Nagata T, Komiyama S, Miyashita A, Hamada T, Kuryu Y, Ikoma H, Kubota T, Kimura A et al. 2010 RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Research 30 2673-2682.
68. Okegawa T, Nutahara K & Higashihara E 2010 Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. International Journal of Urology 17 466-475.
69. Pappas JJ, Toulouse A, Basik M, Levesque L & Bradley WE 2011 Knockdown of RARB2 identifies a dual role in cancer. Genes, Chromosomes & Cancer 50 700-714. (doi:10.1002/gcc.20892)
70. Philipp AB, Stieber P, Nagel D, Neumann J, Spelsberg F, Jung A, Lamerz R, Herbst A & Kolligs FT 2012 Prognostic role of methylated free circulating DNA in colorectal cancer. International Journal of Cancer 131 2308-2319.
71. Ponomaryova AA, Rykova EY, Cherdyntseva NV, Skvortsova TE, Dobrodeev AY, Zav'yalov AA, Bryzgalov LO, Tuzikov SA, Vlassov VV & Laktionov PP 2013 Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 81 397-403. (doi:10.1016/j.lungcan. 2013.05.016)
72. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, Sanchez JM, Moran T, Camps C, Massuti B et al. 2005 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plusgemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. Journal of Clinical Oncology 23 9105-9112. (doi:10.1200/JCO.2005.02.2905)
73. Rodriguez-Paredes M & Esteller M 2011 Cancer epigenetics reaches mainstream oncology. Nature Medicine 17 330-339. (doi:10.1038/nm.2305)
74. Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T et al. 2009 Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Research 29 2619-2625.
75. Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D et al. 2011 First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 72 84-91. (doi:10.1016/j.lungcan. 2010.07.008)
76. Schmidt B, Beyer J, Dietrich D, Bork I, Liebenberg V & Fleischhacker M 2015 Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS ONE 10 e0118195. (doi:10.1371/journal. pone.0118195)
77. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S & Ralhan R 2009 Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell 31 487-500. (doi:10.3233/CLO-2009-0507)
78. Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P & Ralhan R 2010 Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sciences 87 83-91.
79. Sharma G, Mirza S, Parshad R, Gupta SD & Ralhan R 2012 DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biology 33 1837-1843. (doi:10.1007/s13277-012-0443-y)
80. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV & Laktionov PP 2006 Cell-free and cellbound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. British Journal of Cancer 94 1492-1495. (doi:10.1038/sj.bjc.6603117)
81. Stirzaker C, Zotenko E, Song JZ, Qu W, Nair SS, Locke WJ, Stone A, Armstong NJ, Robinson MD, Dobrovic A et al. 2015 Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nature Communications 6 5899. (doi:10.1038/ncomms6899)
82. Tao MH, Shields PG, Nie J, Millen A, Ambrosone CB, Edge SB, Krishnan SS, Marian C, Xie B, Winston J et al. 2009 DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Research and Treatment 114 559-568. (doi:10.1007/s10549-008-0028-z)
83. Tu SP, Sun YW, Cui JT, Zou B, Lin MC, Gu Q, Jiang SH, Kung HF, Korneluk RG & Wong BC 2010 Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression. Cancer 116 1252-1263. (doi:10.1002/cncr.24814)
84. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J & Sukumar S 2001 Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20 3348-3353. (doi:10.1038/sj.onc.1204438)
85. (US) NCI 2014 Biomarker, Imaging and Quality of Life Studies FindingProgram. Bethesda, MD, USA: US Department of Health and Human Services, National Institutes of Health.
86. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr & Kinzler KW 2013 Cancer genome landscapes. Science 339 1546-1558. (doi:10.1126/science.1235122)
87. Wang H, Zhang B, Chen D, Xia W, Zhang J, Wang F, Xu J, Zhang Y, Zhang M, Zhang L et al. 2015 Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer. Clinical Epigenetics 7 119. (doi:10.1186/s13148-015-0150-9)
88. Warton K & Samimi G 2015 Methylation of cell-free circulating DNA in the diagnosis of cancer. Frontiers in Molecular Biosciences 2 13. (doi:10.3389/fmolb.2015.00013)
89. Warton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mangs H, Nair SS, Hacker NF et al. 2014 Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. BMC Genomics 15 476. (doi:10.1186/1471-2164-15-476)
90. Wittenberger T, Sleigh S, Reisel D, Zikan M, Wahl B, Alunni-Fabbroni M, Jones A, Evans I, Koch J, Paprotka T et al. 2014 DNA methylation markers for early detection of women's cancer: promise and challenges. Epigenomics 6 311-327. (doi:10.2217/epi.14.20)
91. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM & Johnson PJ 1999 Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Research 59 71-73.
92. Wong IH, Zhang J, Lai PB, Lau WY & Lo YM 2003 Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clinical Cancer Research 9 1047-1052.
93. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL & Yuen AP 2004 Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clinical Cancer Research 10 2401-2406.
94. Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tamura S, Tsuchiya K, Imamura T et al. 2008 Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clinical Cancer Research 14 7011-7019. (doi:10.1158/1078-0432. CCR-08-1249)
95. Yang Q, Sakurai T & Kakudo K 2002 Retinoid, retinoic acid receptor b and breast cancer. Breast Cancer Research and Treatment 76 167-173. (doi:10.1023/A:1020576606004)
96. Yap TA, Swanton C & de Bono JS 2012 Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA Journal 3 3. (doi:10.1007/s13167-011-0138-2)
97. Yu JL, Lv P, Han J, Zhu X, Hong LL, Zhu WY, Wang XB, Wu YC, Li P & Ling ZQ 2014 Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer. Archives in Pathology and Laboratory Medicine 138 1466-1473. (doi:10.5858/arpa.2013-0285-OA)
98. Zare M, Jazii FR, Alivand MR, Nasseri NK, Malekzadeh R & Yazdanbod M 2009 Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer 9 24. (doi:10.1186/1471-2407-9-24)
99. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN et al. 2008 Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Research 68 2764-2772. (doi:10.1158/0008-5472. CAN-07-6349)
100. Zhu LM, Shi DM, Dai Q, Cheng XJ, Yao WY, Sun PH, Ding Y, Qiao MM, Wu YL, Jiang SH et al. 2014 Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget 5 5403-5415. (doi:10.18632/oncotarget.2114)
101. Zou B, Chim CS, Pang R, Zeng H, Dai Y, Zhang R, Lam CS, Tan VP, Hung IF, Lan HY et al. 2012 XIAP-associated factor 1(XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification. Molecular Carcinogenesis 51 422-432. (doi:10.1002/mc.20807)
102. Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernandez JL, Arrabal SR, Martinez-Galan J, Oliver FJ & Ruiz de Almodovar JM 2010 Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 10 217. (doi:10.1186/1471-2407-10-217)